The price-to-earnings ratio for Biomarin Pharmaceutical Inc (NASDAQ: BMRN) is 28.96x, which is above its average ratio. Moreover, the 36-month beta value for BMRN is
In the past week, BMRN stock has gone up by 3.07%, with a monthly decline of -13.67% and a quarterly plunge of -1.65%. The volatility
The price-to-earnings ratio for Biomarin Pharmaceutical Inc (NASDAQ: BMRN) is above average at 27.29x. The 36-month beta value for BMRN is also noteworthy at 0.31.
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has a higher price-to-earnings ratio of 27.02x compared to its average ratio. BMRN has 36-month beta value of 0.41. Analysts
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has a price-to-earnings ratio of 31.06x that is above its average ratio. Additionally, the 36-month beta value for BMRN is
The stock price of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has plunged by -0.07 when compared to previous closing price of 71.53, but the company has
The stock price of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) has plunged by -0.28 when compared to previous closing price of 71.52, but the company has
© 2024, Powered by Smart TechOne
